EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Azabicyclo Compounds
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Mutation
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptor, Epidermal Growth Factor
  • Small Cell Lung Carcinoma

abstract

  • The findings of this exploratory study suggest that different EGFR TKIs may select for distinct mechanisms of resistance. These results raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer. Further work investigating this hypothesis is warranted.

publication date

  • February 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3261336

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e31823c5aee

PubMed ID

  • 22173702

Additional Document Info

start page

  • 434

end page

  • 42

volume

  • 7

number

  • 2